
Jazz Pharmaceuticals (JAZZ) remains in focus on Tuesday morning after President Donald Trump demanded that the DOJ proceed quickly to reclassify cannabis as a Schedule III drug.
The company spent $7.2 billion to acquire GW Pharmaceuticals in 2021 that added Epidiolex to its portfolio, an FDA-approved cannabidiol-based prescription medicine used to treat severe forms of epilepsy.